United States Biotechnology & Medical Research

Xilio Therapeutics Inc (XLO)

Track

Xilio Therapeutics Inc. has seen no insider trading activity within the last three months. The most recent transaction occurred on March 26, 2026, involving a purchase of shares. Prior activity included a mix of planned sales and open market purchases by various insiders and institutional entities throughout 2025 and early 2026.
Ticker: XLO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Xilio Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 26 Mar 2026
Value US$2,742,173.76 | Price 219.85 | Shares 73,192 (-24.1%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-30 2026-03-26 B Purchase
2.2
Shannon James Samuel
Non-Executive Director
73,192 -24.1%
219.85
US$2,742,174 		73,192 -24.1% 219.85 US$2,742,174
2026-01-05 2026-01-02 PlS Planned sale
Frankenfield Christopher James

Chief Financial Officer

Officer
3,996 -43.9%
87.84
US$1,975,684 		3,996 -43.9% 87.84 US$1,975,684
2026-01-05 2026-01-02 PlS Planned sale
Brennan Kevin M.

SVP, FINANCE AND ACCOUNTING

Officer
90,034 +11.8%
241.22
US$3,425,246 		90,034 +11.8% 241.22 US$3,425,246
2025-06-18 2025-06-17 B Purchase
2.2
Shannon James Samuel
Non-Executive Director
25,000 +55.6%
0.69
US$17,215 		25,000 +55.6% 0.69 US$17,215
2025-06-18 2025-06-16 B Purchase
2.2
Shannon James Samuel
Non-Executive Director
45,000 +inf%
0.69
US$30,870 		45,000 +inf% 0.69 US$30,870
2025-06-18 2025-06-16 B Purchase
3.0
Russo Rene

PRESIDENT AND CEO

Executive Director
36,289 +14.8%
0.68
US$24,680 		36,289 +14.8% 0.68 US$24,680
2025-01-03 2025-01-02 PlS Planned sale
Brennan Kevin M.

SVP, FINANCE AND ACCOUNTING

Officer
1,803 -36.1%
0.98
US$1,774 		1,803 -36.1% 0.98 US$1,774
2025-01-03 2025-01-02 PlS Planned sale
Frankenfield Christopher James

Chief Financial Officer

Officer
6,954 -35.9%
0.98
US$6,841 		6,954 -35.9% 0.98 US$6,841
2024-12-19 2024-12-18 B Purchase
1.3
GILEAD SCIENCES, INC.
Large shareholder
1,759,978 +24.0%
1.04
US$1,830,377 		1,759,978 +24.0% 1.04 US$1,830,377
2024-04-03 2024-04-02 B Purchase
1.3
GILEAD SCIENCES, INC.
Large shareholder
485,250 +7.1%
0.76
US$368,790 		485,250 +7.1% 0.76 US$368,790
2024-02-09 2024-02-08 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
267 -0.0%
0.64
US$171 		267 -0.0% 0.64 US$171
2024-02-09 2024-02-08 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
733 -0.0%
0.64
US$469 		733 -0.0% 0.64 US$469
2024-01-16 2024-01-12 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
560 -0.1%
0.83
US$465 		560 -0.1% 0.83 US$465
2024-01-16 2024-01-12 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
1,540 -0.1%
0.83
US$1,278 		1,540 -0.1% 0.83 US$1,278
2024-01-16 2024-01-11 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
569 -0.1%
0.87
US$495 		569 -0.1% 0.87 US$495
2024-01-16 2024-01-11 S Sale
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
1,566 -0.1%
0.87
US$1,362 		1,566 -0.1% 0.87 US$1,362
2021-12-10 2021-12-10 B Purchase
2.7
Bain Capital Life Sciences Investors, LLC
Large shareholder
3,188 +0.1%
10.24
US$32,638 		3,188 +0.1% 10.24 US$32,638
2021-12-10 2021-12-10 B Purchase
2.7
Bain Capital Life Sciences Investors, LLC
Large shareholder
21,812 +0.8%
9.56
US$208,564 		21,812 +0.8% 9.56 US$208,564
2021-12-10 2021-12-09 B Purchase
2.7
Bain Capital Life Sciences Investors, LLC
Large shareholder
4,011 +0.1%
9.84
US$39,485 		4,011 +0.1% 9.84 US$39,485
2021-12-10 2021-12-08 B Purchase
2.7
Bain Capital Life Sciences Investors, LLC
Large shareholder
13,458 +0.5%
9.62
US$129,474 		13,458 +0.5% 9.62 US$129,474
2021-10-28 2021-10-26 B Purchase
2.8
Flynn James E
Large shareholder
387,500 +51.2%
16.00
US$6,200,000 		387,500 +51.2% 16.00 US$6,200,000
2021-10-28 2021-10-26 B Purchase
2.8
Flynn James E
Large shareholder
387,500 +51.2%
16.00
US$6,200,000 		387,500 +51.2% 16.00 US$6,200,000
2021-10-26 2021-10-26 B Purchase
2.0
Atlas Venture Fund XI, L.P.
Large shareholder
187,500 +34.2%
16.00
US$3,000,000 		187,500 +34.2% 16.00 US$3,000,000
2021-10-26 2021-10-26 B Purchase
2.8
Rock Springs Capital Management LP
Large shareholder
500,000 +66.1%
16.00
US$8,000,000 		500,000 +66.1% 16.00 US$8,000,000
2021-10-26 2021-10-26 B Purchase
2.1
BAY CITY CAPITAL LLC
Large shareholder
312,500 +38.3%
16.00
US$5,000,000 		312,500 +38.3% 16.00 US$5,000,000
2021-10-26 2021-10-26 B Purchase
1.6
RiverVest Venture Fund IV, L.P.
Large shareholder
250,000 +21.0%
16.00
US$4,000,000 		250,000 +21.0% 16.00 US$4,000,000
Explore more

More insider trading research around Xilio Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America